PRQRN Stock Chart & Stats
$29.63
$5.00(16.67%)
At close: 4:00 PM EDT
$29.63
$5.00(16.67%)
Day’s Range― - ―
52-Week Range$28.50 - $36.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$4.08B
Enterprise Value$85.70M
Total Cash (Recent Filing)$117.08M
Total Debt (Recent Filing)$13.19M
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Nov 05, 2026EPS Estimate
-2.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding138,087,650
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.12
Price to Sales (P/S)11.85
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$149.97Price Target Upside406.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-7.71
Revenue Forecast (FY)$305.52M
Bulls Say, Bears Say
Bulls Say
Revenue Rebound And High Gross MarginsThe sharp revenue rebound and very high gross margin indicate meaningful economic potential in ProQR’s partnered and licensing-oriented model. If growth persists as programs advance, strong gross margins could provide substantial operating leverage once development spending and commercial scale improve.
Strengthened Liquidity And Cash RunwayThe equity financing and resulting cash balance provide resources to fund multiple clinical programs over the medium term. A runway extending into mid-2028 reduces immediate financing pressure and supports continued development, milestone generation, and platform investment without relying solely on near-term capital access.
Axiomer Platform Advancing Into Clinical ValidationProgression of an AI-discovered candidate into human testing, alongside reported improvements in RNA editing efficiency, strengthens evidence that Axiomer can generate differentiated programs. Additional clinical readouts and broader platform application could improve partnering appeal and diversify future development opportunities.
Bears Say
Deep Ongoing LossesProQR remains far from break-even despite revenue improvement, so its current operations do not yet support themselves financially. Persistent net and operating losses can erode equity, constrain strategic flexibility, and require continued funding before clinical programs can produce durable commercial returns.
Substantial Cash BurnMeaningfully negative operating and free cash flow shows that research and clinical development consume considerably more cash than the business generates. Continued burn raises the importance of future financings, collaborations, or milestone receipts and could increase dilution or funding risk if programs take longer to advance.
Reliance On Collaborations Before Product CommercializationThe absence of marketed products leaves ProQR dependent on partner funding, licensing receipts, milestones, and potential royalties rather than recurring product sales. These sources can be uneven and contingent on development progress, while the company continues carrying substantial R&D costs ahead of commercialization.
ProQR News
PRQRN FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $28.50 and its highest was $36.00 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $4.08B.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Nov 05, 2026 which is in 30 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Aug 13, 2026. The company reported -$1.622 earnings per share for the quarter, beating the consensus estimate of -$2.311 by $0.689.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -2.05.
How many shares outstanding does ProQR have?
ProQR has 138,087,650 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$1.622 in its last earnings report, beating expectations of -$2.311. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in MX:PRQRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$149.97 (406.14% Upside)
$149.97 (406.14% Upside)
Blogger Sentiment
Bullish
MX:PRQRN Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $19.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ProQR
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
PRQRN Stock 12 Month Forecast
Average Price Target
$149.97
▲(406.14% Upside)